Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.
Tatyana Feldman, MD
Advertisement
Articles by Tatyana Feldman, MD
Advertisement
Latest Updated Articles
Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLLPublished: December 15th 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
3
FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC
4
Nogapendekin Alfa Combo Shows Survival Benefits in BCG-Unresponsive NMIBC
5